A Phase 1 Randomized, Double Blind, Placebo Controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of NGM120 in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 21 Aug 2019
Price : $35 *
At a glance
- Drugs NGM-120 (Primary)
- Indications Cachexia
- Focus Adverse reactions
- Sponsors NGM Biopharmaceuticals
- 12 Aug 2019 Results published in the NGM Biopharmaceuticals Media Release.
- 12 Aug 2019 Status changed from recruiting to completed,according to an NGM Biopharmaceuticals Media release.
- 03 Apr 2018 Status changed from not yet recruiting to recruiting.